Karl Doerner
About Karl Doerner
Karl Doerner serves as the Associate Director of Non Clinical Operations at Tenaya Therapeutics, bringing over 20 years of experience in small molecule and antibody pharmacology. He has contributed to the development of three FDA-approved therapeutics and has held various research roles in prominent biotechnology companies.
Work at Tenaya Therapeutics
Karl Doerner currently serves as the Associate Director of Non Clinical Operations at Tenaya Therapeutics, a position he has held since 2024. In this role, he oversees nonclinical operations, contributing to the advancement of investigational therapies. Prior to this position, he worked as a Senior Manager of Nonclinical Operations at Tenaya Therapeutics from 2022 to 2024. His experience at Tenaya Therapeutics emphasizes his commitment to drug development and operational excellence within the biotechnology sector.
Education and Expertise
Karl Doerner holds a Bachelor of Science and Master of Science in Biochemistry from UMass Boston, where he studied from 1999 to 2002. He also studied Music and Chemistry at the University of Oregon from 1993 to 1997. With over 20 years of experience in small molecule and antibody pharmacology, he has developed a strong foundation in both scientific research and operational management within the pharmaceutical industry.
Background in Pharmaceutical Research
Karl Doerner has a diverse background in pharmaceutical research, having worked at several prominent organizations. He began his career at Sugen Inc as a Research Associate from 2002 to 2003. He then joined Genentech as a Research Associate II from 2004 to 2007, followed by a position as a Senior Research Associate at FibroGen from 2007 to 2008. He served as a Scientist at Rinat - Pfizer from 2008 to 2015 and at Nurix Therapeutics from 2015 to 2022, gaining extensive experience in drug development processes.
Achievements in Drug Development
Throughout his career, Karl Doerner has worked on numerous Investigational New Drug (IND) candidates and has contributed to the development of three FDA-approved therapeutics. His extensive experience in both nonclinical operations and scientific research has positioned him as a knowledgeable professional in the field of pharmacology, particularly in the development of small molecules and antibodies.